Ascendis Pharma
$227.87Change from previous close: +0.25%Absolute change: +$0.56
At a glance
- Revenue growth
- +98.03%
- 2025 vs 2024
- Net margin
- -31.7%
- 2024: -104.0%
Financial data
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | 53.9 | -306 | -467 | -496 | — |
| Depreciation and amortization | 17.7 | 17.7 | 18.9 | 18.0 | — |
| Capital expenditure | -8.5 | -1.4 | -2.4 | -14.5 | — |
| Investing cash flow | -8.5 | 6.9 | 286 | 61.7 | — |
| Financing cash flow | 36.3 | 444 | 134 | 397 | — |
| Share repurchases | -17.4 | 0.0 | 0.0 | -105 | — |
| Debt issued | 0.0 | 134 | 136 | 503 | — |
| Debt repaid | -22.0 | -11.4 | -10.4 | -6.4 | — |
| Effect of exchange rates | -25.2 | 22.8 | -6.0 | 35.7 | — |
| Net change in cash | 81.7 | 145 | -46.6 | -37.2 | — |
| Free cash flow | 45.4 | -308 | -470 | -510 | — |